ArticleOncology letters2026
Intravascular large B-cell lymphoma mimicking an orbital mass lesion and bilateral cavernous sinus syndrome: A case report.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intravascular large B-cell lymphoma (IVLBCL) is a rare entity that can present with atypical extranodal manifestations, often mimicking other orbital or neurological conditions. A 69-year-old woman presented with rapidly progressive left ptosis and diplopia, which progressed to complete bilateral ophthalmoplegia within several weeks. Magnetic resonance imaging revealed a previously unreported right orbital mass accompanied by bilateral cavernous sinus (CS) enhancement, representing a novel imaging feature of IVLBCL. The diagnosis was established by sphenoid sinus biopsy. The patient achieved near-clinical remission, with almost complete resolution of the orbital mass, following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) chemotherapy combined with a Bruton tyrosine kinase inhibitor and intravenous high-dose methotrexate. However, diplopia recurred at 3 months post-treatment, indicating that although the patient initially responded well to R-CHOP-based combination therapy, more effective maintenance or consolidation strategies should be actively explored for patients with IVLBCL involving the central nervous system. Clinically, various lymphoma subtypes should be considered in the differential diagnosis of patients presenting with CS and intraorbital lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.